About Tiziana Life Sciences PLC (LON:TILS)
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.
Industry, Sector and Symbol:
Capitalization:- Market Cap: £141 million
- Outstanding Shares: 94,393,000
Average Prices:- 50 Day Moving Avg: GBX 151.80
- 200 Day Moving Avg: GBX 176.23
- 52 Week Range: GBX 102.06 - GBX 240
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.04 per share
- Price / Book: 42.68
Profitability:- EBITDA: ($7,280,000.00)
- Return on Equity: -188.71%
- Return on Assets: -151.53%
Misc:- Average Volume: 5,036 shs.
Frequently Asked Questions for Tiziana Life Sciences PLC (LON:TILS)
What is Tiziana Life Sciences PLC's stock symbol?
Tiziana Life Sciences PLC trades on the London Stock Exchange (LON) under the ticker symbol "TILS."
How were Tiziana Life Sciences PLC's earnings last quarter?
Tiziana Life Sciences PLC (LON:TILS) released its quarterly earnings results on Friday, September, 29th. The company reported ($4.10) EPS for the quarter, missing the consensus estimate of ($2.00) by $2.10. View Tiziana Life Sciences PLC's Earnings History.
Where is Tiziana Life Sciences PLC's stock going? Where will Tiziana Life Sciences PLC's stock price be in 2017?
1 brokers have issued 1 year price targets for Tiziana Life Sciences PLC's shares. Their forecasts range from GBX 400 to GBX 400. On average, they anticipate Tiziana Life Sciences PLC's stock price to reach GBX 400 in the next twelve months. View Analyst Ratings for Tiziana Life Sciences PLC.
Who are some of Tiziana Life Sciences PLC's key competitors?
Some companies that are related to Tiziana Life Sciences PLC include Capital Southwest Corporation (CSWC), Draper Esprit PLC (GROW), Saratoga Investment Corp (SAR), CM Finance (CMFN), Gresham House plc (GHE), Cluff Natural Resources PLC (CLNR), Mineral & Financial Investments Ltd (MAFL), Legendary Investments plc (LEG), Amedeo Resources PLC (AMED), Amedeo Resources PLC (CRO), Greencoat UK Wind PLC (UKW), Henderson Global Trust PLC (HGL), International Biotechnology Trust Plc (IBT), iShares S&P NA Tec. Semi. Idx. Fd.(ETF) (SOXX), ProShares UltraShort Russell2000 (TWM), Standard Life Equity Income Trust Plc (SLET) and Tiziana Life Sciences PLC (ADI).
Who are Tiziana Life Sciences PLC's key executives?
Tiziana Life Sciences PLC's management team includes the folowing people:
- Gabriele M. Cerrone, Executive Chairman of the Board
- Kunwar Shailubhai Ph.D., Chief Executive Officer, Chief Scientific Officer, Director
- Tiziano Lazzaretti, Chief Financial Officer
- James Tripp, Chief Operating Officer, Head of Global Clinical Operations
- P. Cooper, Company Secretary
- Percy W. C. Lomax, Non-Executive Director
- Willy Jules Simon, Non-Executive Director
How do I buy Tiziana Life Sciences PLC stock?
Shares of Tiziana Life Sciences PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Tiziana Life Sciences PLC's stock price today?
One share of Tiziana Life Sciences PLC stock can currently be purchased for approximately GBX 149.38.
MarketBeat Community Rating for Tiziana Life Sciences PLC (LON TILS)MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Tiziana Life Sciences PLC (LON:TILS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | GBX 400 |
Consensus Price Target History for Tiziana Life Sciences PLC (LON:TILS)
Analysts' Ratings History for Tiziana Life Sciences PLC (LON:TILS)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 10/2/2017 | Beaufort Securities | Reiterated Rating | Speculative Buy | GBX 400 |  |
(Data available from 10/18/2015 forward)
Earnings History for Tiziana Life Sciences PLC (LON:TILS)Earnings History by Quarter for Tiziana Life Sciences PLC (LON TILS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/29/2017 | S1 2017 | GBX (2) | GBX (4.10) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Tiziana Life Sciences PLC (LON:TILS)Current Year EPS Consensus Estimate: $-1.700 EPS
Dividend History for Tiziana Life Sciences PLC (LON:TILS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Tiziana Life Sciences PLC (LON:TILS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Tiziana Life Sciences PLC (LON:TILS)
Latest Headlines for Tiziana Life Sciences PLC (LON:TILS)
| Source: |
|
Tiziana Life Sciences PLC (TILS) Chart for Wednesday, October, 18, 2017
